Literature DB >> 3571853

Effect of thyrotoxicosis and its treatment on mineral and bone metabolism.

J D Lalau, J L Sebert, A Marie, A Fournier, J Quichaud.   

Abstract

Mineral metabolism and bone histomorphometric status were evaluated in 31 hyperthyroid patients (HT) without clinical or radiological bone disease, both before and after treatment of hyperthyroidism. Blood and urine biochemical data were compared with those obtained in sex and age-matched controls. Iliac bone biopsies were available from 12 untreated HT and from 6 of them after treatment for analysis of trabecular bone. Mean plasma calcium was increased in HT but true hypercalcemia was seen in only one case and mean plasma immunoreactive parathormone (iPTH) was normal. Urine calcium excretion was markedly increased, especially in the fasting state. Biochemical parameters decreased after treatment, except for serum alkaline phosphatase and iPTH that, respectively, remained high and increased. Untreated state was characterized by an hyperremodelling state with enhanced activities of bone formation and bone resorption. Bone mineralization was normal. The mineral and bone changes were related to serum thyroid hormone levels. After treatment, the extent of formation surfaces still increased. The fact that, even though calcium metabolism abnormalities were corrected, active resorption surfaces did not change, suggests that trabecular osteoclastic resorption is not an important cause of mobilization of bone calcium to extracellular fluids in HT.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3571853     DOI: 10.1007/BF03346972

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  29 in total

1.  Treatment of thyrotoxic hypercalcemia with propranolol.

Authors:  R K Rude; S B Oldham; F R Singer; J T Nicoloff
Journal:  N Engl J Med       Date:  1976-02-19       Impact factor: 91.245

2.  Ionized and total serum calcium and parathyroid hormone in hyperthyroidism.

Authors:  K D Burman; J M Monchik; J M Earll; L Wartofsky
Journal:  Ann Intern Med       Date:  1976-06       Impact factor: 25.391

3.  Hyperthyroidism and calcium metabolism.

Authors:  D A Smith; S A Fraser; G M Wilson
Journal:  Clin Endocrinol Metab       Date:  1973-07

4.  Effect of antithyroid treatment on calcium-phosphorus metabolism in hyperthyroidism. I: Chemical quantities in serum and urine.

Authors:  L Mosekilde; M S Christensen; F Melsen; N S Sørensen
Journal:  Acta Endocrinol (Copenh)       Date:  1978-04

5.  Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism.

Authors:  L Mosekilde; F Melsen; J P Bagger; O Myhre-Jensen; N Schwartz Sorensen
Journal:  Acta Endocrinol (Copenh)       Date:  1977-07

6.  Serum levels of vitamin D metabolites and bone remodelling in hyperthyroidism.

Authors:  B Jastrup; L Mosekilde; F Melsen; B Lund; B Lund; O H Sørensen
Journal:  Metabolism       Date:  1982-02       Impact factor: 8.694

7.  Effect of hyperthyroidism and its treatment on bone mineral content.

Authors:  S H Toh; B C Claunch; P H Brown
Journal:  Arch Intern Med       Date:  1985-05

8.  [Fasting urinary excretion of calcium, phosphorus and hydroxyproline in relation to creatinine. Normal values and correlations with 24-hour urine values (author's transl)].

Authors:  J L Sebert; G Cornaille; M P San Juan; T D Kha; F Blotman; L Simon
Journal:  Nouv Presse Med       Date:  1981-09-26

9.  Tissue sources of elevated serum alkaline phosphatase activity in hyperthyroid patients.

Authors:  D P Rhone; F G Berlinger; F M White
Journal:  Am J Clin Pathol       Date:  1980-10       Impact factor: 2.493

10.  Influence of thyroid function on the serum concentration of 1,25-dihydroxyvitamin D3.

Authors:  R Bouillon; E Muls; P De Moor
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

View more
  1 in total

1.  Bone turnover in hyperthyroidism before and after thyrostatic management.

Authors:  G C Isaia; C Roggia; D Gola; M D Stefano; G Gallone; G Aimo; P Ardissone; M Mussetta
Journal:  J Endocrinol Invest       Date:  2000-12       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.